iBio (IBIO) Common Equity (2011 - 2026)
iBio (IBIO) posted quarterly Common Equity of $77.5 million for Q1 2026, up 581.28% year-over-year from $11.4 million in Q1 2025, and up 37.09% quarter-over-quarter from $56.6 million in Q4 2025.
iBio (IBIO) Common Equity (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Common Equity for 16 consecutive years, with $77.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 581.28% year-over-year to $77.5 million; the TTM figure through Mar 2026 stood at $77.5 million (up 581.28% YoY), while the FY2025 annual figure was $14.9 million, down 30.22% from the prior year.
- Common Equity improved to $77.5 million in Q1 2026 per IBIO's latest filing, from $56.6 million in the prior quarter.
- Across five years, Common Equity topped out at $79.4 million in Q1 2022 and bottomed at $9.2 million in Q4 2023.
- Historically, Common Equity has averaged $32.9 million across 5 years, with a median of $18.8 million in 2022.
- Annual changes were most pronounced in 2022 — Common Equity plunged 79.22% — and 2026, when it surged 581.28%.
- iBio's Common Equity stood at $18.8 million in 2022, then plunged by 51.14% to $9.2 million in 2023, then jumped by 51.08% to $13.9 million in 2024, then surged by 307.05% to $56.6 million in 2025, then surged by 37.09% to $77.5 million in 2026.
- Business Quant data shows IBIO's Common Equity at $77.5 million in Q1 2026, $56.6 million in Q4 2025, and $56.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 9.79 Bn |
| 10 | iBio | 178.80 Mn | 178.80 Mn | - | 77.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.54 Mn |
| Dec 31, 2025 | 56.56 Mn |
| Sep 30, 2025 | 56.04 Mn |
| Jun 30, 2025 | 14.88 Mn |
| Mar 31, 2025 | 11.38 Mn |
| Dec 31, 2024 | 13.90 Mn |
| Sep 30, 2024 | 17.75 Mn |
| Jun 30, 2024 | 21.32 Mn |
| Mar 31, 2024 | 24.86 Mn |
| Dec 31, 2023 | 9.20 Mn |
| Sep 30, 2023 | 13.21 Mn |
| Jun 30, 2023 | 15.38 Mn |
| Mar 31, 2023 | 17.39 Mn |
| Dec 31, 2022 | 18.82 Mn |
| Sep 30, 2022 | 48.37 Mn |
| Jun 30, 2022 | 63.49 Mn |
| Mar 31, 2022 | 79.38 Mn |
| Dec 31, 2021 | 90.60 Mn |
| Sep 30, 2021 | 100.53 Mn |
| Jun 30, 2021 | 108.57 Mn |